The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

Danielle S. Cha,Nicholas Kleine,Kayla M. Teopiz,Joshua D. Di Vincenzo,Roger Ho,Stephanie L. Galibert,Amrita Samra,Samuel P.M. Zilm,Rebekah H. Cha,Giacomo d’Andrea,Hartej Gill,Felicia Ceban,Shakila Meshkat,Sabrina Wong,Gia Han Le,Angela T.H Kwan,Joshua D. Rosenblat,Taeho Greg Rhee,Rodrigo B. Mansur,Roger S. McIntyre
DOI: https://doi.org/10.1080/14656566.2023.2298340
2024-01-25
Expert Opinion on Pharmacotherapy
Abstract:Introduction Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners. Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABA A receptors, is an attractive alternative as a rapid-acting antidepressant treatment.
pharmacology & pharmacy
What problem does this paper attempt to address?